Thinking About a Wegovy 3 Month Supply? Here's What to Consider

Why the dose you're on changes how much three months actually is

Wegovy's standard pathway starts at 0.25 mg weekly, then steps up through 0.5 mg, 1.0 mg, 1.7 mg to the 2.4 mg maintenance dose, with each step lasting around four weeks. That means if you're just starting out, three months covers approximately three of those steps, each at a different strength. A single pen contains four doses, so in rough arithmetic a three-month stretch uses three pens, but they won't all be the same pen.

Once you've reached 2.4 mg and your prescriber is happy to maintain that dose, three months becomes more predictable: three pens of the same strength, one after another. The MHRA also approved a higher 7.2 mg maintenance dose in January 2026, and a dedicated single-dose 7.2 mg pen followed in April 2026, so depending on where you are in treatment and what your prescriber recommends, the picture could look different again. The semaglutide overview on our treatment pages covers how the full schedule works.

The practical point is that "three months of Wegovy" isn't a single product to pick off a shelf. It's a sequence determined by your clinical notes, your response to treatment so far, and what a prescriber judges appropriate at each review. Planning ahead is sensible; if you're concerned about availability, our page on whether Wegovy is currently in short supply sets out the current picture honestly so you can plan accordingly.

The review that sits between month one and month three

Regulated UK pharmacies don't and shouldn't hand over three months of a prescription-only medicine in one go without checking in. At nume, every repeat order is reviewed by a GPhC-registered Independent Prescriber before it's approved. That means someone reads your updated weight, any side effects you've reported, and whether the current dose is working, not software, a real clinician. The review is the point of the process, not an obstacle to it.

This matters more than it might sound. The NICE appraisal of semaglutide for weight management recommends reviewing patients after six months to check whether at least 5% body weight has been lost on maintenance dose, if not, continuing treatment is reconsidered. A three-month supply that bypasses clinical oversight removes that safeguard entirely.

If you're wondering whether ongoing supply is available and what stock looks like right now, our page on the current state of Wegovy supply in the UK sets out the position honestly. Shortages have been a recurring issue; knowing what to expect helps you plan rather than panic.

What three months of private Wegovy supply looks like with a regulated pharmacy

Through a service like ours, treatment doesn't arrive as a bulk box. Each order follows its own clinical review. Once approved, the pen ships the same day from our GPhC-registered pharmacy and arrives the next working day via DPD in plain, unbranded packaging. You get a tracking notification on your phone and the pen arrives ready for the fridge, discreet, cold-chain intact.

From a cost perspective, three months means three separate monthly orders, each including the consultation review, prescription and delivery. There are no subscriptions and no auto-renewals. If you want to understand what goes into the pricing of a month's supply before committing further, our guide to a one-month Wegovy supply breaks down what a single order covers and what legitimate pricing in the UK tends to look like.

It's also worth knowing that if at any point you want to pause, your prescriber can advise on that too. Stopping Wegovy has its own considerations (weight can return relatively quickly after treatment ends) so that's a conversation worth having rather than a decision made by simply not reordering.

Eligibility and who this three-month plan is realistically for

Wegovy is licensed in the UK for adults (not under-18s) with a BMI of 30 or above, or 27 to 29.9 alongside a weight-related health condition. Lower BMI thresholds can apply for some ethnic backgrounds under UK guidance. These are the licensed parameters; your prescriber assesses your full picture, including medications you already take, your medical history and any conditions that might make semaglutide unsuitable.

Pregnancy, breastfeeding and trying to conceive are all situations where Wegovy is not recommended. Anyone planning surgery should let their anaesthetist and surgical team know they're on a GLP-1 medicine. The NHS patient information for semaglutide covers contraindications and when to seek urgent medical help, the kind of detail that's worth reading before starting rather than after.

On the NHS, Wegovy is available only through specialist weight management services under strict criteria, and waiting lists are commonly long. Private treatment through a regulated pharmacy is the practical alternative for people who meet the clinical criteria but don't want to wait. If you're still working out which treatment fits your situation, our guide to what Wegovy month 3 typically involves can help you understand where treatment is likely to be heading by that point, and the weight loss treatment page sets out all the options we can assess you for.